| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Brummett RE | |
| Fox KE | |||
| P2860 | cites work | Controlled Comparison of Amikacin and Gentamicin | Q28324094 |
| Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity | Q28327774 | ||
| Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail | Q28330792 | ||
| Neomycin Ototoxicity | Q28332199 | ||
| Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report | Q28332511 | ||
| Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis | Q28361867 | ||
| Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides | Q28361967 | ||
| Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin | Q28366502 | ||
| Prospective comparative study of efficacy and toxicity of netilmicin and amikacin | Q33723887 | ||
| Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity | Q33727669 | ||
| Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | Q34055509 | ||
| Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin | Q34056699 | ||
| Future trends in aminoglycoside therapy | Q38592466 | ||
| Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infections | Q39106011 | ||
| Prevention of hearing impairment from infection and ototoxic drugs | Q39494691 | ||
| Why Monitor Serum Levels of Gentamicin? | Q39725314 | ||
| Aminoglycoside toxicity in infants and children | Q39738115 | ||
| Netilmicin: A Review of Toxicity in Laboratory Animals | Q39771096 | ||
| Therapeutic initiatives for the avoidance of aminoglycoside toxicity | Q39818301 | ||
| An overview of amikacin | Q39819199 | ||
| Link between functional and morphological changes in the inner ear--functional changes produced by ototoxic agents and their interactions | Q39841342 | ||
| Netilmicin (Netromycin, Schering-Plough). | Q40144922 | ||
| Ototoxicity: etiology and issues | Q40145161 | ||
| Netilmicin in the treatment of Pseudomonas bacteremia | Q69945594 | ||
| Dibekacin in the newborn: pharmacokinetics and evaluation of ototoxicity in neonates and premature infants | Q70733379 | ||
| The Aminoglycosides | Q71001687 | ||
| A prospective, randomized study of amikacin and gentamicin in serious infections with focus on efficacy, toxicity and duration of serum levels above the MIC | Q71104190 | ||
| Aminoglycoside antibiotics in the treatment of otologic infections | Q71586707 | ||
| Aminoglycoside ototoxicity | Q72083146 | ||
| Bobbing oscillopsia from gentamicin toxicity | Q72110441 | ||
| Observations on the toxicity of the combination of gentamicin and mezlocillin in the treatment of patients with acute leukaemia | Q72830452 | ||
| Recent otological evaluation of aminoglycoside antibiotics | Q40170712 | ||
| Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. | Q40310512 | ||
| Drug-induced sudden hearing loss and vestibular disturbances | Q40323176 | ||
| Streptomycin sulphate and deafness: a review of the literature | Q40325489 | ||
| Gentamicin-induced ototoxicity in a carefully monitored renal-failure patient | Q40355018 | ||
| Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy | Q40694970 | ||
| Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms | Q40791217 | ||
| A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. | Q40807990 | ||
| A controlled study of the reliability of pure tone audiometry for the detection of gentamicin auditory toxicity | Q41452622 | ||
| The use of pure-tone audiometry in the assessment of gentamicin auditory toxicity | Q41459881 | ||
| Proper use of aminoglycosides | Q41539806 | ||
| Ototoxicity of commonly used pharmaceutical preparations | Q41716158 | ||
| A prospective study of high-frequency auditory function in patients receiving oral neomycin | Q42207623 | ||
| Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin | Q42225000 | ||
| Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial | Q42240379 | ||
| Aminoglycoside-induced cochlear pathology in man. | Q42245599 | ||
| Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis | Q42248893 | ||
| Effect of 'high-dose' amikacin in children | Q42251137 | ||
| Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis | Q42258591 | ||
| Ototoxicity of netilmicin. | Q42261988 | ||
| Netilmicin: chemical development and overview of clinical research | Q42262371 | ||
| Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study | Q42267486 | ||
| Altered objective audiometry in aminoglycosides-treated human neonates | Q42273140 | ||
| Profound bilateral sensorineural hearing loss during gentamicin therapy | Q43422777 | ||
| Vestibular ototoxicity of prophylactic aminoglycoside antibiotics in head and neck cancer patients | Q44543172 | ||
| Clinical assessment of newer antibiotics. Effect in compromised hosts and drug combinations. | Q44643044 | ||
| Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides | Q45006893 | ||
| Auditory brainstem response in young burn-wound patients treated with ototoxic drugs | Q48270552 | ||
| Evaluation of the renal and auditory function of neonates treated with amikacin | Q49034703 | ||
| [Hearing loss, a complication of antibiotic therapy in severely burned patients] | Q50574359 | ||
| Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. | Q50579015 | ||
| Qualitative overview of randomized trials of aminoglycosides. | Q50579019 | ||
| Vestibulo-ocular reflexes in peripheral labyrinthine lesions: III. Bilateral dysfunction. | Q50582821 | ||
| Aminoglycoside ototoxicity. An update, with implications for all drug therapies. | Q50584059 | ||
| Clinical monitoring of the effects of gentamicin by electrocochleography. | Q50589537 | ||
| Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. | Q50589543 | ||
| Hearing can be lost during healing. | Q50589710 | ||
| Ototoxicity. | Q50594397 | ||
| Comment on aminoglycoside evaluation. | Q50594932 | ||
| Plasma concentration monitoring of aminoglycosides | Q50600623 | ||
| The influence of ototoxic drugs on brainstem auditory evoked potentials in man. | Q50603774 | ||
| Prospective evaluation of vestibular and auditory function in 76 patients treated with netilmicin. | Q50608537 | ||
| Netilmicin treatment followed by monitoring of vestibular and auditory function using highly sensitive methods. | Q50608541 | ||
| Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report. | Q50608619 | ||
| Aminoglycoside-ototoxicity. The role of investigational technique and the influence of patient condition on test results. | Q50608631 | ||
| Netilmicin: Clinical Evaluation of Efficacy and Toxicity of a New Aminoglycoside | Q50614007 | ||
| Ototoxicity of gentamicin: clinical experience in a children's hospital | Q50619275 | ||
| KANAMYCIN OTOTOXICITY IN HEALTHY MEN. | Q50683542 | ||
| The aminoglycosides. | Q54524442 | ||
| Nephrotoxicity: a comparison in humans of gentamicin and gentamicin C1 administration | Q67372444 | ||
| Aminoglycoside ototoxicity | Q68796326 | ||
| A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin | Q68833375 | ||
| Antibiotic prophylaxis in vascular reconstructive surgery: a double-blind placebo-controlled study | Q68861404 | ||
| A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis | Q69171370 | ||
| Drug-induced ototoxicity | Q69511075 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hearing loss | Q16035842 |
| P304 | page(s) | 797-800 | |
| P577 | publication date | 1989-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Aminoglycoside-induced hearing loss in humans | |
| P478 | volume | 33 |
| Q46926447 | A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. |
| Q42278836 | Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection |
| Q38514140 | Allergic Reactions in Hospitalized Patients With a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem |
| Q37774277 | Aminoglycoside antibiotics: structure, functions and effects on in vitro plant culture and genetic transformation protocols |
| Q44905354 | Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases |
| Q95806228 | Aminoglycosides--50 years on |
| Q33548221 | Aminoglycosides: activity and resistance |
| Q28138065 | Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance |
| Q35746986 | An update on otolaryngology in critical care |
| Q43139342 | Antibiotic Driven Changes in Gut Motility Suggest Direct Modulation of Enteric Nervous System |
| Q38006505 | Antimicrobial therapy for the elderly patient |
| Q30838132 | Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up |
| Q37060143 | Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis |
| Q37139410 | Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. |
| Q47211006 | Bayesian pharmacokinetics of gentamicin in a haemodialysis population |
| Q35109053 | Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model |
| Q45191205 | Chemoprophylactic and bactericidal efficacy of 80 mg gentamicin in a single and once-daily dosing. |
| Q36156077 | Combination therapy for treatment of infections with gram-negative bacteria |
| Q27318102 | Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort |
| Q35885240 | Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children |
| Q50315312 | Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment |
| Q40902529 | Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity |
| Q40947010 | Drug-induced tinnitus and other hearing disorders |
| Q34004443 | Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa |
| Q37771799 | Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind. |
| Q37661512 | Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis |
| Q33936855 | Global problem of drug-induced hearing loss |
| Q50431707 | High rate of unperceived hearing loss in patients after liver transplantation |
| Q51761592 | Impact of Aging on the Auditory System and Related Cognitive Functions: A Narrative Review. |
| Q35912654 | Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy |
| Q46894652 | Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women |
| Q89278554 | Intact Cell Lipidomics Reveal Changes to the Ratio of Cardiolipins to Phosphatidylinositols in Response to Kanamycin in HeLa and Primary Cells |
| Q34509828 | Involvement of reactive oxygen species in the action of ciprofloxacin against Escherichia coli |
| Q42908869 | Management of Aminoglycosides in the Intensive Care Unit |
| Q44607744 | Memantine's action against aminoglycoside-induced ototoxicity |
| Q77831918 | Multidrug-resistant tuberculosis |
| Q33545113 | Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? |
| Q40143423 | Once-daily aminoglycoside dosing: A new look at an old drug |
| Q37730823 | Once-daily aminoglycoside therapy |
| Q35127266 | Once-daily aminoglycoside therapy: potential ototoxicity |
| Q34985783 | Once-daily aminoglycosides in patients with neutropenic fever |
| Q37811204 | Oral Infections and Antibiotic Therapy |
| Q38653146 | Ototoxicity (cochleotoxicity) classifications: A review |
| Q39510044 | Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial |
| Q34521641 | Ototoxicity induced by gentamicin and furosemide |
| Q37961280 | Paediatric use of second-line anti-tuberculosis agents: a review |
| Q28328534 | Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q45822404 | Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia |
| Q37626510 | Polymyxins and analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro. |
| Q33772759 | Prevention of adverse events in hospitalized patients using an antimicrobial review program |
| Q35693590 | Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models |
| Q39030684 | Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis |
| Q34752229 | Risk factors for toxicity in elderly patients given aminoglycosides once daily. |
| Q92497796 | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
| Q42150030 | Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease |
| Q55664007 | Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis. |
| Q36134894 | Studying outcomes of intensive care unit survivors: the role of the cohort study |
| Q34874579 | Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss |
| Q74025503 | Systemic absorption of gentamicin ear drops |
| Q27321070 | Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research |
| Q37268122 | The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients |
| Q36317060 | The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia |
| Q40317145 | The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. |
| Q37409465 | Therapeutic drug monitoring of aminoglycosides in neonates |
| Q40915627 | Therapeutic drug monitoring of antimicrobials |
| Q26829604 | Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis |
| Q90699541 | Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites |
| Q34529303 | Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance |
| Q52881617 | What is the evidence for once-daily aminoglycoside therapy? |
| Q36446781 | d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models |
Search more.